Skip to main content
micro-community-banner
 
  • Saved

Commented on 's Post

Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients - PubMed

doi: 10.3389/fonc.2021.647598. 1 Radiotherapy Department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. 2 Department of Thoracic Surgery, Affiliated Hospital of Hebei University, Baoding, China. 3 Department of Medical ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33898318/

Show More Comments

  • 1 day 2 hours
    Key Points • In the current study, Chinese researchers mined sequenced data from 36,813 unselected lung cancer patients who were profiled for somatic mutations. They looked at eight lung cancer genes Show More
  • Saved

made a Post

63-Year-Old Female with Vision Disturbances and Headaches

Evelyn, who is 63, presents to her primary care physician, complaining of headaches, visual disturbances, and fatigue. Her medical history includes hypertension ..... see more

  • Saved

made a Post

Implementation of clinical sequencing for molecular profiling in patients with advanced cancer - PubMed

doi: 10.3233/CBM-200781. Online ahead of print. 1 Department of Respiratory Medicine, Kitasato University School of Medicine, Kanagawa, Japan. 2 Department of Genome Biology, Kindai University Faculty of Medicine, Osaka, Japan. ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33896820/

  • Saved

made a Post

Amgen Provides Updated Information On LUMAKRAS™ (Sotorasib)¹ Dose Comparison Study

THOUSAND OAKS, Calif., April 28, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it agreed last night with the FDA's proposed post-marketing requirement to conduct, as part of the ..... see more

Source : https://www.prnewswire.com/news-releases/amgen-provides-updated-information-on-lumakras-sotorasib-dose-comparison-study-301278732.html

  • Saved

made a Post

Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort - PubMed

doi: 10.1159/000514648. Online ahead of print. 1 Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico. 2 Clinical and Traslational Oncology Group, Clínica del Country, Bogotá, Colombia. 3 ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33902046/

Arturo Loaiza Bonilla, Vijay Rao Commented on a Post
  • Saved

Historically considered undruggable, KRAS mutations have gained significant attention due to recent KRAS inhibitor clinical trials. KRAS is the most frequently mutated oncogene, occurring in approximately 20-25% of all cancers. The frequency and distribution of KRAS mutations varies depending on the type of cancer, and they are most predominant in pancreatic ductal adenocarcinoma, colorectal cancer, and non-small lung cancer.

KRAS mutations are typically considered prognostic biomarkers, as they are indicative of poor patient outcomes irrespective of treatment. KRAS mutations also commonly occur in a mutually exclusive fashion with other genetic mutations and alterations. Given this, many treatment guidelines recommend including KRAS testing in situations where molecular testing is appropriate.

Do you test for KRAS mutations at diagnosis and what method do you use? If you do not test at initial diagnosis, do you test at relapse? How do these test results play into your decision-making regarding treatment?

Show More Comments

  • 5 days 20 hours
    We use NGS for all advanced NSCLC, and if KRAS G12C, both TKIs are very promising. I would consider using them before Chemo immunotherapy. The issue is secondary mutations to Show More
  • 1 week
    I test for KRAS mutations, it is done with NGS.
  • Saved

Commented on 's Post

Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5'-deoxy-5-fluorocytidine (5'-DFCR) - PubMed

doi: 10.1186/s13046-021-01938-2. 1 Department of General Thoracic Surgery, Inselspital, Bern University Hospital, Murtenstrasse 50, 3008, Bern, Switzerland. 2 Department of BioMedical Research, University of Bern, Bern, Switzerland. 3 Institute of ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33874986/

Show More Comments

  • 1 week 2 days
    Key Points • Combined therapy with pemetrexed (MTA) and cisplatin in patients with advanced non-small cell lung cancer is the standard of care, however the 5-year survival rate is fewer than 10% Show More
  • Saved

made a Post

In Vitro Anti-cancer Activity of Adipose-Derived Mesenchymal Stem Cells Increased after Infection with Oncolytic Reovirus - PubMed

Purpose: Reovirus type 3 Dearing (ReoT3D), a wild type oncolytic virus (OV) from the Reoviridae family, kills KRAS mutant cancer cells. However, the use of OVs has faced with some ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33880359/

  • Saved

made a Post

Spatially interacting phosphorylation sites and mutations in cancer - PubMed

1 Department of Genetics and Genomics, Tisch Cancer Institute, Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. kuan-lin.huang@mssm.edu. 2 ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33875650/

  • Saved

made a Post

SOD1 regulates ribosome biogenesis in KRAS mutant non-small cell lung cancer - PubMed

SOD1 is known as the major cytoplasmic superoxide dismutase and an anticancer target. However, the role of SOD1 in cancer is not fully understood. Herein we describe the generation of ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33859191/

42-Year-Old Non-Smoker Diagnosed with NSCLC

Samantha is a 42-year-old mother of two. She was athletic — playing basketball in college and running mini-marathons in her 30s. She ..... see more

Show More Comments

  • from Pathologist Connect 1 week 4 days
    clinical trial with KRAS G12C inhibitor
  • 2 weeks 3 days
    @Kumar - while I agree the standard of care is clear, my message was to develop a clinical trial to solve the question, unless the data from PACIFIC already included Show More
  • Saved

Commented on 's Post

Show More Comments

  • 2 weeks 1 day
    Key Points • Novel study examining the correlation between KRAS status with outcomes following ICI monotherapy compared with that of chemoimmunotherapy in patients with PD-L1 of 50% or greater. • KRAS variants in NSCLC Show More
  • Saved

made a Post

Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation - PubMed

1 Massachusetts General Hospital. 2 Medical Oncology, Massachusetts General Hospital. 3 Department of Medicine, Massachusetts General Hospital. 4 Cancer Center, Massachusetts General Hospital. 5 Massachusetts General Hospital Cancer Center. 6 ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33824136/

  • Saved

made a Post

Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer

Maroni, Bassal, Krishnan et al. characterise human non-small cell lung cancer (NSCLC) carrying Kras-mutations by single-cell RNA sequencing. They identify a tumour-specific population that is conserved in mice and responds ..... see more

Source : https://www.nature.com/articles/s42003-021-01897-6

  • Saved

from Pathologist Connect made a Post

In a new study published online today in JAMA Oncology, researchers show that patients harboring a KRAS gene mutation with high levels of PDL-1 lived longer when treated with immunotherapy ..... see more

Immunotherapy Alone Extended Life for Metastatic Lung Cancer Patients with KRAS Mutation - Penn Medicine

Real-word evidence is suggesting, for the first time, the most beneficial treatment courses that could help extend the lives of patients with metastatic non-small cell lung cancer, according to research ..... see more

Source : https://www.pennmedicine.org/news/news-releases/2021/april/immunotherapy-alone-extended-life-for-metastatic-lung-cancer-patients-with-kras-mutation

  • Saved

made a Post


TITLE: Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients ..... see more

Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC - PubMed

1 Department of Pathology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis And Thoracic Tumor Research Institute, Beijing, China. 2 Medical Department, Amoy Diagnostics Co., Ltd., Xiamen, China. 3 Department ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33656807/

  • Saved

made a Post

Prognostic impact of KRAS G12C mutation in patients with NSCLC: results from the ETOP Lungscape Project - PubMed

1 St. James Hospital, Institute of Molecular Medicine, Dublin, Ireland. Electronic address: stephen.finn@tcd.ie. 2 University Hospital Geneva, Department of Oncology, Geneva, Switzerland. 3 Frontier Science Foundation-Hellas, ETOP Statistics Center and ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33647504/

  • Saved

made a Post

Performance evaluation of a fully closed real-time PCR platform for the detection of KRAS p.G12C mutations in liquid biopsy of patients with non-small cell lung cancer - PubMed

Whenever tissue sample is not available, non-small cell lung cancer (NSCLC) biomarker testing is performed with liquid biopsy. The Kirsten rat sarcoma viral oncogene homolog ( KRAS ) p.G12C mutation ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33649142/

  • Saved

made a Post

Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer - PubMed

In the scenario of systemic treatment for advanced non-small cell lung cancer (NSCLC) patients, one of the most relevant breakthroughs is represented by targeted therapies. Throughout the last years, inhibitors ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33807876/